NEOG (Health Care Supplies) Stock Valuation & Fair Value Poor on forward returns
NEOG (Health Care Supplies) trades at a blended P/E of 38.8, about 14% below its historical normal valuation, with a forward growth estimate of 15.5% and a PEG of 2.50. Analysts' one-year estimates have been hit 45% of the time. Priced at its historical normal P/E of 45.3 on the same blended earnings, the 2026-10-02 close of $12.15 corresponds to about $14.20 a share. This is a valuation reference, not a price target.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is NEOG overvalued?
At a blended P/E of 38.8 versus its historical normal P/E of 45.3, NEOG trades about 14% below its typical valuation, with a PEG of 2.50 on 15.5% forward growth. tickerseer currently rates it poor on forward returns.
What is NEOG's fair value and PEG?
NEOG trades at a blended P/E of 38.8 against a historical normal P/E of 45.3, a PEG of 2.50, and a forward growth estimate of 15.5%. Priced at its historical normal P/E of 45.3 on the same blended earnings, the 2026-10-02 close of $12.15 corresponds to about $14.20 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of NEOG changed?
tickerseer's rating has been poor on forward returns since 2026-10-03.
Industry: Health Care Supplies. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.